JP2017527591A - 認知機能向上のための植物抽出物 - Google Patents
認知機能向上のための植物抽出物 Download PDFInfo
- Publication number
- JP2017527591A JP2017527591A JP2017514456A JP2017514456A JP2017527591A JP 2017527591 A JP2017527591 A JP 2017527591A JP 2017514456 A JP2017514456 A JP 2017514456A JP 2017514456 A JP2017514456 A JP 2017514456A JP 2017527591 A JP2017527591 A JP 2017527591A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- day
- plant
- sleep
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003920 cognitive function Effects 0.000 title claims description 27
- 239000000419 plant extract Substances 0.000 title claims description 12
- 239000000284 extract Substances 0.000 claims abstract description 55
- 230000015654 memory Effects 0.000 claims abstract description 50
- 230000007958 sleep Effects 0.000 claims abstract description 48
- 230000036651 mood Effects 0.000 claims abstract description 25
- 230000004633 cognitive health Effects 0.000 claims abstract description 20
- 230000006872 improvement Effects 0.000 claims abstract description 20
- 230000006399 behavior Effects 0.000 claims abstract description 12
- 241000207923 Lamiaceae Species 0.000 claims abstract description 11
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract 5
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract 5
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract 5
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims description 98
- 238000000034 method Methods 0.000 claims description 66
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims description 49
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims description 49
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims description 49
- 208000010877 cognitive disease Diseases 0.000 claims description 24
- 241000196324 Embryophyta Species 0.000 claims description 20
- 244000024873 Mentha crispa Species 0.000 claims description 15
- 235000014749 Mentha crispa Nutrition 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 14
- 230000013016 learning Effects 0.000 claims description 14
- 230000002618 waking effect Effects 0.000 claims description 13
- 235000013824 polyphenols Nutrition 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 11
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 11
- 208000028698 Cognitive impairment Diseases 0.000 claims description 10
- 230000006870 function Effects 0.000 claims description 9
- 230000007423 decrease Effects 0.000 claims description 8
- 235000002020 sage Nutrition 0.000 claims description 8
- 244000178870 Lavandula angustifolia Species 0.000 claims description 7
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 7
- 241001072983 Mentha Species 0.000 claims description 7
- 230000037007 arousal Effects 0.000 claims description 7
- 239000001102 lavandula vera Substances 0.000 claims description 7
- 235000018219 lavender Nutrition 0.000 claims description 7
- 235000014435 Mentha Nutrition 0.000 claims description 5
- 206010024264 Lethargy Diseases 0.000 claims description 4
- 206010016256 fatigue Diseases 0.000 claims description 3
- 230000004620 sleep latency Effects 0.000 claims description 3
- 235000013628 Lantana involucrata Nutrition 0.000 claims 4
- 235000005135 Micromeria juliana Nutrition 0.000 claims 4
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 claims 4
- 235000010676 Ocimum basilicum Nutrition 0.000 claims 4
- 240000007926 Ocimum gratissimum Species 0.000 claims 4
- 235000011203 Origanum Nutrition 0.000 claims 4
- 240000000783 Origanum majorana Species 0.000 claims 4
- 240000007673 Origanum vulgare Species 0.000 claims 4
- 244000178231 Rosmarinus officinalis Species 0.000 claims 4
- 241000246354 Satureja Species 0.000 claims 4
- 235000007315 Satureja hortensis Nutrition 0.000 claims 4
- 235000007303 Thymus vulgaris Nutrition 0.000 claims 4
- 240000002657 Thymus vulgaris Species 0.000 claims 4
- 239000001585 thymus vulgaris Substances 0.000 claims 4
- 230000008092 positive effect Effects 0.000 abstract description 3
- 229940105022 spearmint extract Drugs 0.000 description 55
- 238000012360 testing method Methods 0.000 description 25
- 239000000902 placebo Substances 0.000 description 23
- 229940068196 placebo Drugs 0.000 description 23
- 238000011282 treatment Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 230000009469 supplementation Effects 0.000 description 21
- 230000001154 acute effect Effects 0.000 description 20
- 230000003936 working memory Effects 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 19
- 230000001976 improved effect Effects 0.000 description 17
- 230000032683 aging Effects 0.000 description 15
- 230000001684 chronic effect Effects 0.000 description 15
- 230000037396 body weight Effects 0.000 description 11
- 230000006999 cognitive decline Effects 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 9
- 230000003931 cognitive performance Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000341 volatile oil Substances 0.000 description 9
- 244000062730 Melissa officinalis Species 0.000 description 8
- 235000010654 Melissa officinalis Nutrition 0.000 description 8
- 230000019771 cognition Effects 0.000 description 8
- 230000001149 cognitive effect Effects 0.000 description 8
- 230000003340 mental effect Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- 230000003542 behavioural effect Effects 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 206010027175 memory impairment Diseases 0.000 description 7
- 230000035882 stress Effects 0.000 description 7
- 206010012289 Dementia Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 229940112822 chewing gum Drugs 0.000 description 6
- 235000015218 chewing gum Nutrition 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000003860 sleep quality Effects 0.000 description 6
- 230000007596 spatial working memory Effects 0.000 description 6
- 244000194101 Ginkgo biloba Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 208000019022 Mood disease Diseases 0.000 description 5
- 240000004371 Panax ginseng Species 0.000 description 5
- 240000003444 Paullinia cupana Species 0.000 description 5
- 235000000556 Paullinia cupana Nutrition 0.000 description 5
- 230000003930 cognitive ability Effects 0.000 description 5
- 235000008434 ginseng Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000006996 mental state Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001502 supplementing effect Effects 0.000 description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 235000008100 Ginkgo biloba Nutrition 0.000 description 4
- 241001529742 Rosmarinus Species 0.000 description 4
- 244000258095 Salvia lavandulifolia Species 0.000 description 4
- 235000001500 Salvia lavandulifolia Nutrition 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000002516 radical scavenger Substances 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 208000031404 Chromosome Aberrations Diseases 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 244000126014 Valeriana officinalis Species 0.000 description 3
- 235000013832 Valeriana officinalis Nutrition 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000021196 dietary intervention Nutrition 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000011194 food seasoning agent Nutrition 0.000 description 3
- 235000021472 generally recognized as safe Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000007787 long-term memory Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000003924 mental process Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 235000016788 valerian Nutrition 0.000 description 3
- 230000036642 wellbeing Effects 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 208000019914 Mental Fatigue Diseases 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- 231100000107 OECD 471 Bacterial Reverse Mutation Test Toxicity 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N carnosic acid Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 231100000005 chromosome aberration Toxicity 0.000 description 2
- 231100000762 chronic effect Toxicity 0.000 description 2
- 229960001284 citicoline Drugs 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000001073 episodic memory Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- PSFDQSOCUJVVGF-UHFFFAOYSA-N harman Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C PSFDQSOCUJVVGF-UHFFFAOYSA-N 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- 230000008642 heat stress Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000008449 language Effects 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000001220 mentha spicata Substances 0.000 description 2
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000003649 prolyl endopeptidase inhibitor Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 230000006403 short-term memory Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- YSTPAHQEHQSRJD-SECBINFHSA-N (-)-piperitone Chemical compound CC(C)[C@H]1CCC(C)=CC1=O YSTPAHQEHQSRJD-SECBINFHSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 206010000503 Acne cystic Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 206010070246 Executive dysfunction Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 241001072909 Salvia Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003935 attention Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 230000036992 cognitive tasks Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 235000021137 habitual diet Nutrition 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 230000028252 learning or memory Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- -1 memory Chemical compound 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 230000006883 memory enhancing effect Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940029985 mineral supplement Drugs 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000020772 multivitamin supplement Nutrition 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 229930003811 natural phenol Natural products 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000002352 nonmutagenic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000010490 psychological well-being Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000004617 sleep duration Effects 0.000 description 1
- 230000008454 sleep-wake cycle Effects 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000021193 standardized breakfast Nutrition 0.000 description 1
- 238000012030 stroop test Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
- 230000006438 vascular health Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本開示の理解を容易にするために、以下の定義を設ける。
スペアミント抽出物の有効性試験を行い、老化を加速させたSAMP8マウスモデルにおける学習及び記憶の向上の可能性を評価した(米国特許出願第13/962,609号、本出願は2013年8月8日出願され、参照によって本明細書に組み込まれる)。SAMP8マウスにスペアミント抽出物又は媒体対照を投与した。更に、SAMP8の50%戻し交配系にも媒体を投与して対照として使用した。90日間治療を行った後のマウスに、T−迷路の足へのショック回避、対象認識及びレバー押しを含む3種の行動試験を行った。スペアミント抽出物により、T−迷路試験における獲得(16mg(活性成分)/kg(体重)及び32mg(活性成分)/kg(体重)の両方で)及び保持(すべての投与量で)が向上した。更に、ロスマリン酸を含むスペアミントにより、16及び32mg/kg(体重)での対象認識を向上した。16mg(活性成分)/kg(体重)及び32mg(活性成分)/kg(体重)のマウスに対する用量は、ヒト当量用量では、91〜180mgのロスマリン酸、即ち約15%の活性成分を含む600〜1200mgのスペアミント抽出物に相当する。これらの結果から、スペアミントからの抽出物が、SAMP8マウスの加齢に伴って生じる学習及び記憶の欠損に有益な効果を有するが分かった。
無作為二重盲検プラセボ対照試験で、年齢関連記憶障害(age-associated memory impairment:AAMI)を有する男性及び女性の認知能力、睡眠、気分及び耐容性の尺度でスペアミント抽出物の効果を評価した。この研究の目的は、AAMIを有する男性及び女性の認知機能の側面に対する2用量(600mg又は900mg)での独占所有権のあるスペアミント抽出物の急性効果及び慢性効果を評価することであった。
Claims (50)
- 有効量のシソ(Lamiaceae)科植物抽出物を投与することを含み、前記抽出物の主要な活性成分はロスマリン酸及び植物ポリフェノールである、哺乳動物の認知的健康及び/又は機能を向上、改善又は持続させる方法。
- 前記哺乳類はヒト又は伴侶動物である、請求項1に記載の方法。
- 前記植物はバジル、ミント、セージ、セイボリー、マジョラム、オレガノ、タイム、ラベンダー、スペアミント、及びローズマリーからなる群から選択される、請求項1に記載の方法。
- 前記植物はハッカ(Mentha)属から選択される、請求項1に記載の方法。
- 前記抽出物は少なくとも8重量%のロスマリン酸を含む、請求項1に記載の方法。
- 前記有効量は0.01mg/kg/日〜50mg/kg/日である、請求項1に記載の方法。
- 前記有効量は600mg/日〜900mg/日の範囲の経口用量である、請求項1に記載の方法。
- 前記抽出物は一定の間隔で投与される、請求項1に記載の方法。
- 前記抽出物は少なくとも1日1回投与される、請求項8に記載の方法。
- 前記抽出物の投与は学習、実行機能、記憶、気分又は睡眠を改善する、請求項1に記載の方法。
- 前記抽出物の投与は生活の質を改善する、請求項1に記載の方法。
- 有効量のシソ科植物抽出物を投与することを含み、前記抽出物の主要な活性成分はロスマリン酸及び植物ポリフェノールである、哺乳動物の認知的健康及び/又は機能の低下を治療又は予防するための方法。
- 前記哺乳類はヒト又は伴侶動物である、請求項12に記載の方法。
- 前記植物はバジル、ミント、セージ、セイボリー、マジョラム、オレガノ、タイム、ラベンダー、スペアミント、及びローズマリーからなる群から選択される、請求項12に記載の方法。
- 前記植物はハッカ属から選択される、請求項12に記載の方法。
- 前記抽出物は少なくとも8重量%のロスマリン酸を含む、請求項12に記載の方法。
- 前記抽出物の有効量は0.01mg/kg/日〜50mg/kg/日である、請求項12に記載の方法。
- 前記有効量は600mg/日〜900mg/日の範囲の経口用量である、請求項12に記載の方法。
- 前記抽出物は一定の間隔で投与される、請求項12に記載の方法。
- 前記抽出物は少なくとも1日1回投与される、請求項19に記載の方法。
- 前記抽出物は少なくとも45日間毎日投与される、請求項19に記載の方法。
- 前記抽出物の投与は学習、実行機能、記憶、気分又は睡眠を維持する、請求項12に記載の方法。
- 前記抽出物の投与は生活の質を改善する、請求項12に記載の方法。
- 前記植物抽出物の投与はストレスによって引き起こされる認知機能の障害を防止する、請求項12に記載の方法。
- 有効量のシソ科植物抽出物を投与することを含み、前記抽出物の主要な活性成分はロスマリン酸及び植物ポリフェノールである、哺乳動物の気分を改善する方法。
- 前記哺乳類はヒト又は伴侶動物である、請求項25に記載の方法。
- 前記植物はバジル、ミント、セージ、セイボリー、マジョラム、オレガノ、タイム、ラベンダー、スペアミント、及びローズマリーからなる群から選択される、請求項25に記載の方法。
- 前記植物はハッカ属から選択される、請求項25に記載の方法。
- 前記抽出物は少なくとも8重量%のロスマリン酸を含む、請求項25に記載の方法。
- 前記抽出物の有効量は0.01mg/kg/日〜50mg/kg/日である、請求項25に記載の方法。
- 前記有効量は600mg/日〜900mg/日の範囲の経口用量である、請求項25に記載の方法。
- 前記抽出物は一定の間隔で投与される、請求項25に記載の方法。
- 前記抽出物は少なくとも1日1回投与される、請求項32に記載の方法。
- 前記抽出物は少なくとも45日間毎日投与される、請求項32に記載の方法。
- 前記抽出物の投与は活気、活力、エネルギー、又は覚醒を改善する、請求項25に記載の方法。
- 活気、活力、エネルギー又は覚醒の前記改善は抑うつ、落込み、疲労又は嗜眠の増加がなく起こる、請求項35に記載の方法。
- 気分の改善はPOMSによって測定される、請求項25に記載の方法。
- 有効量のシソ科植物抽出物を投与することを含み、前記抽出物の主要な活性成分はロスマリン酸及び植物ポリフェノールである、哺乳動物の睡眠を改善する方法。
- 哺乳動物はヒト又は伴侶動物である、請求項38に記載の方法。
- 前記植物はバジル、ミント、セージ、セイボリー、マジョラム、オレガノ、タイム、ラベンダー、スペアミント、及びローズマリーからなる群から選択される、請求項38に記載の方法
- 前記植物はハッカ属から選択される、請求項38に記載の方法。
- 前記抽出物は少なくとも8重量%のロスマリン酸を含む、請求項38に記載の方法。
- 前記抽出物の有効量は0.01mg/kg/日〜50mg/kg/日である、請求項38に記載の方法。
- 前記有効量は600mg/日〜900mg/日の範囲の経口用量である、請求項38に記載の方法。
- 前記抽出物は一定の間隔で投与される、請求項38に記載の方法。
- 前記抽出物は少なくとも1日1回投与される、請求項45に記載の方法。
- 前記抽出物は少なくとも45日間毎日投与する、請求項45に記載の方法。
- 前記抽出物の投与は睡眠潜時を短縮する、請求項38に記載の方法。
- 前記抽出物の投与は入眠能力又は目覚め後の行動を改善する、請求項38に記載の方法。
- 前記睡眠の改善はLSEQによって測定される、請求項38に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022051706A JP2022084873A (ja) | 2014-09-15 | 2022-03-28 | 認知機能向上のための植物抽出物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462050563P | 2014-09-15 | 2014-09-15 | |
US62/050,563 | 2014-09-15 | ||
PCT/US2015/050230 WO2016044299A1 (en) | 2014-09-15 | 2015-09-15 | Plant extracts for improving cognitive function |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022051706A Division JP2022084873A (ja) | 2014-09-15 | 2022-03-28 | 認知機能向上のための植物抽出物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017527591A true JP2017527591A (ja) | 2017-09-21 |
JP2017527591A5 JP2017527591A5 (ja) | 2018-09-27 |
Family
ID=55453722
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017514456A Pending JP2017527591A (ja) | 2014-09-15 | 2015-09-15 | 認知機能向上のための植物抽出物 |
JP2022051706A Pending JP2022084873A (ja) | 2014-09-15 | 2022-03-28 | 認知機能向上のための植物抽出物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022051706A Pending JP2022084873A (ja) | 2014-09-15 | 2022-03-28 | 認知機能向上のための植物抽出物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US10857195B2 (ja) |
EP (1) | EP3194028A4 (ja) |
JP (2) | JP2017527591A (ja) |
KR (2) | KR20240000637A (ja) |
AU (1) | AU2015317990B2 (ja) |
BR (1) | BR112017005133A2 (ja) |
CA (1) | CA2961378A1 (ja) |
WO (1) | WO2016044299A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004167218A (ja) * | 2002-10-28 | 2004-06-17 | Takasago Internatl Corp | 消臭剤組成物 |
CN1566300A (zh) * | 2003-07-09 | 2005-01-19 | 新疆芳香植物科技开发股份有限公司 | 制造香囊、香枕的芳香组合物及其制备方法 |
JP2005053891A (ja) * | 2003-07-18 | 2005-03-03 | Seresu Corporation:Kk | リパーゼ阻害剤 |
CN102014943A (zh) * | 2008-02-25 | 2011-04-13 | 雀巢产品技术援助有限公司 | 包含例如迷迭香或葛缕子提取物的用于促进骨生长和维持骨健康的营养组合物 |
JP2013085554A (ja) * | 2011-10-21 | 2013-05-13 | Yang Song | エゴマの葉マッコリ及びその製造方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4752476A (en) * | 1986-02-18 | 1988-06-21 | Copney Claudette V | Sleep aiding herbal composition and method of utilizing same |
US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
JP2002275061A (ja) * | 2001-03-19 | 2002-09-25 | Tsumura & Co | 抗うつ・抗不安剤 |
US20050031761A1 (en) * | 2003-08-05 | 2005-02-10 | Donald Brucker | Methods of producing a functionalized coffee |
JP2006199666A (ja) * | 2005-01-24 | 2006-08-03 | Nagase & Co Ltd | 健忘症の予防・治療剤 |
EP1930019A1 (en) * | 2006-11-24 | 2008-06-11 | DSMIP Assets B.V. | Rosemary extracts, dietary and pharmaceutical compositions containing them and their uses |
US20100137433A1 (en) * | 2007-01-24 | 2010-06-03 | Laima Kott | Production of Rosmarinic Acid from Spearmint and uses Thereof |
WO2008122099A1 (en) * | 2007-04-05 | 2008-10-16 | Iomedix Development International Srl | Composition for promoting sleep and relaxation comprising lemon balm |
DK2060192T3 (en) * | 2007-10-17 | 2016-02-22 | Wild Gmbh & Co Kg Rudolf | Composition comprising lemon balm extracts |
JP2012518618A (ja) * | 2009-02-20 | 2012-08-16 | ディーエスエム アイピー アセッツ ビー.ブイ. | 機敏さのためのオレガノ抽出物 |
TW201125569A (en) * | 2009-12-21 | 2011-08-01 | Biotropics Malaysia Berhad | Orthosiphon stamineus extracts for use as a cognition enhancer |
US20140044813A1 (en) * | 2012-08-09 | 2014-02-13 | Kemin Industries, Inc. | Plant Extracts for Improving Cognitive Health and Function |
US20140302170A1 (en) * | 2013-04-08 | 2014-10-09 | Scientific Nutrition Products, Inc. | Compositions and methods for promoting sleep |
BR112016017612A2 (pt) * | 2014-01-30 | 2022-07-12 | Kemin Ind Inc | Uso de um extrato de uma planta do gênero mentha da família lamiaceae |
-
2015
- 2015-09-15 EP EP15841428.4A patent/EP3194028A4/en active Pending
- 2015-09-15 CA CA2961378A patent/CA2961378A1/en active Pending
- 2015-09-15 JP JP2017514456A patent/JP2017527591A/ja active Pending
- 2015-09-15 WO PCT/US2015/050230 patent/WO2016044299A1/en active Application Filing
- 2015-09-15 KR KR1020237043652A patent/KR20240000637A/ko active Search and Examination
- 2015-09-15 US US14/855,003 patent/US10857195B2/en active Active
- 2015-09-15 KR KR1020177010105A patent/KR20170054501A/ko active Application Filing
- 2015-09-15 BR BR112017005133A patent/BR112017005133A2/pt not_active Application Discontinuation
- 2015-09-15 AU AU2015317990A patent/AU2015317990B2/en active Active
- 2015-12-08 US US14/962,537 patent/US20160166629A1/en active Pending
-
2022
- 2022-03-28 JP JP2022051706A patent/JP2022084873A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004167218A (ja) * | 2002-10-28 | 2004-06-17 | Takasago Internatl Corp | 消臭剤組成物 |
CN1566300A (zh) * | 2003-07-09 | 2005-01-19 | 新疆芳香植物科技开发股份有限公司 | 制造香囊、香枕的芳香组合物及其制备方法 |
JP2005053891A (ja) * | 2003-07-18 | 2005-03-03 | Seresu Corporation:Kk | リパーゼ阻害剤 |
CN102014943A (zh) * | 2008-02-25 | 2011-04-13 | 雀巢产品技术援助有限公司 | 包含例如迷迭香或葛缕子提取物的用于促进骨生长和维持骨健康的营养组合物 |
JP2013085554A (ja) * | 2011-10-21 | 2013-05-13 | Yang Song | エゴマの葉マッコリ及びその製造方法 |
Non-Patent Citations (2)
Title |
---|
FASEB J, vol. Vol.28, No.1, Suppl.1, JPN6019032040, April 2014 (2014-04-01), pages 402, ISSN: 0004283822 * |
酒井 重男: "われわれの健康を支える機能性食品(下)", 食品工業 第54巻第16号, vol. 第54巻, JPN6019032041, ISSN: 0004283823 * |
Also Published As
Publication number | Publication date |
---|---|
BR112017005133A2 (pt) | 2018-01-23 |
CA2961378A1 (en) | 2016-03-24 |
JP2022084873A (ja) | 2022-06-07 |
US10857195B2 (en) | 2020-12-08 |
KR20240000637A (ko) | 2024-01-02 |
KR20170054501A (ko) | 2017-05-17 |
WO2016044299A1 (en) | 2016-03-24 |
EP3194028A4 (en) | 2018-10-10 |
US20160166629A1 (en) | 2016-06-16 |
AU2015317990B2 (en) | 2020-04-30 |
US20160074459A1 (en) | 2016-03-17 |
EP3194028A1 (en) | 2017-07-26 |
AU2015317990A1 (en) | 2017-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dietz et al. | An intervention study on the effect of matcha tea, in drink and snack bar formats, on mood and cognitive performance | |
Farokhnia et al. | N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study | |
JP7360267B2 (ja) | 認知機能を向上させるための植物抽出物 | |
Khayat et al. | Curcumin attenuates severity of premenstrual syndrome symptoms: A randomized, double-blind, placebo-controlled trial | |
Dimitriou et al. | The use of aromatherapy for postoperative pain management: A systematic review of randomized controlled trials | |
Savica et al. | Prevention of dementia | |
CN104271141B (zh) | 富含鞣花单宁提取物的组合物 | |
JP2005290379A (ja) | 生理・心理的治療効果を有する香料組成物 | |
Naureen et al. | Proposal of a food supplement for the management of post-COVID syndrome. | |
JP2022084873A (ja) | 認知機能向上のための植物抽出物 | |
JP2024075715A (ja) | 睡眠を改善するための植物抽出物 | |
Recart et al. | Therapeutic approaches employing natural compounds and derivatives for treating bipolar disorder: emphasis on experimental models of the manic phase | |
Morgan et al. | Outcomes of self-help efforts in anxiety disorders | |
Bongartz et al. | Sleep Promoting Effects of IQP‐AO‐101: A Double‐Blind, Randomized, Placebo‐Controlled Exploratory Trial | |
Tarfarosh et al. | Search for a perfect Nootropic supplement combination –Can we increase human intelligence by nutritional supplements? | |
Eric Zielinski et al. | The Essential Oils Apothecary: Advanced Strategies and Protocols for Chronic Disease and Conditions | |
CA3056731A1 (en) | Compositions comprising essential oils for topical use | |
Kelly et al. | Integrative Approaches to Cognitive Decline | |
Lesch et al. | Therapeutic Strategies in Alcohol and Tobacco Addiction: The Psychology of Motivation and Change in Addiction: From Neuroscience to Clinical Practice | |
Diamond et al. | Complementary, alternative, and integrative medicine in the treatment and management of dementia | |
Alqudah et al. | Effects of Coriandrum sativum seeds on memory, anxiety, depression, and sleep quality in students: a randomized controlled study | |
JP2021048795A (ja) | 脳機能低下抑制剤 | |
文鐘玉 | A combination of nutrients and exercise for prevention of Alzheimer’s disease | |
Fog | Brain Fog: How to Naturally Get Rid of Brain Fatigue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180820 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180820 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190821 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200117 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200612 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20201012 |
|
C116 | Written invitation by the chief administrative judge to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C116 Effective date: 20201026 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20201026 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20210902 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20210908 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20211124 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20211126 |
|
C28A | Non-patent document cited |
Free format text: JAPANESE INTERMEDIATE CODE: C2838 Effective date: 20211126 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220328 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220407 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20220603 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20220701 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20220701 |